…
Xenitra Limited operates as a brand acceleration, market-access, and distribution company in Australia, Hong Kong, and Mainland China. It offers functional and medical food, such as infant formula, and vitamin mineral and supplement category products; over the counter products, such as non-prescription small molecule medicines and structure function benefit complementary medicines; fast-moving consumer goods (FMCG); nutraceuticals; health and wellness; and personal care products, as well as involved in real world asset tokenisation and nutritional product trading. It sells its products through a network of B2B wholesale, retail distribution, and e-commerce platforms. The company was formerly known as AuMake Limited and changed its name to Xenitra Limited in March 2026. Xenitra Limited was incorporated in 2011 and is based in Brisbane, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Xenitra Limited is an Australian-listed company; publicly available disclosures about its business, assets and operations are limited. Because details are sparse, major long-term growth drivers are unclear and will depend on future disclosure about strategy, asset development or revenue generation, so investors may find the company of interest only if management provides clearer evidence of scalable operations or valuable assets.
Key investment risks include information and liquidity risk, potential lack of operating revenues, dependence on external financing, small-cap market volatility and execution risk.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -5.38M | -3.40M | -6.24M | -2.95M | -6.21M |
| Minority interest | - | -0.08M | -0.04M | -0.08M | 0.03M |
| Net income | -5.18M | -3.48M | -6.28M | -3.03M | -6.18M |
| Selling general administrative | - | 4.09M | 2.79M | 2.14M | 4.09M |
| Gross profit | -2.25M | 0.97M | 0.84M | 0.06M | 0.55M |
| Reconciled depreciation | - | 0.09M | 0.39M | 0.46M | 1.34M |
| Ebit | -5.54M | - | - | - | - |
| Ebitda | -5.47M | - | - | - | - |
| Depreciation and amortization | 0.07M | - | - | - | - |
| Operating income | -5.54M | -3.48M | -2.43M | -2.56M | -4.90M |
| Other operating expenses | 25.65M | - | - | - | - |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.01M | 0.01M | 0.01M | 0.02M |
| Net interest income | - | 0.01M | 0.01M | 0.01M | 0.02M |
| Total revenue | 20.11M | 39.77M | 25.87M | 2.67M | 6.01M |
| Total operating expenses | 3.30M | - | - | - | - |
| Cost of revenue | 22.36M | 38.80M | 25.02M | 2.61M | 5.46M |
| Total other income expense net | 0.17M | 0.07M | -3.83M | -0.39M | -1.32M |
| Net income from continuing ops | - | -3.40M | -6.24M | -2.95M | -6.21M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 4.44M | 8.30M | 4.42M | 6.37M | 10.08M |
| Intangible assets | 0.11M | - | - | 4.20M | - |
| Other current assets | 0.72M | - | - | - | - |
| Total liab | 4.26M | 5.64M | 3.80M | 1.26M | 5.98M |
| Total stockholder equity | 0.25M | 2.55M | 0.52M | 5.11M | 4.13M |
| Other current liab | 0.99M | - | - | - | - |
| Common stock | 67.36M | - | - | - | - |
| Capital stock | - | 64.57M | 59.08M | 57.42M | 53.81M |
| Retained earnings | -67.00M | -63.55M | -60.72M | -54.69M | -51.77M |
| Good will | - | - | - | - | 4.50M |
| Cash | 3.16M | 1.68M | 1.99M | 1.39M | 3.04M |
| Total current liabilities | 4.16M | 5.50M | 1.54M | 1.26M | 5.92M |
| Current deferred revenue | 1.05M | - | - | - | - |
| Net debt | -1.94M | - | 0.21M | - | - |
| Short term debt | 1.11M | - | - | - | - |
| Short long term debt | - | 1.03M | 0.03M | - | - |
| Short long term debt total | 1.21M | - | - | - | - |
| Total current assets | 4.09M | 7.89M | 3.85M | 1.92M | 4.61M |
| Long term investments | - | 0.19M | 0.20M | 0.08M | 0.08M |
| Short term investments | - | 0.05M | 0.05M | 0.16M | - |
| Net receivables | 0.21M | 3.00M | 0.53M | 0.01M | 0.08M |
| Long term debt | - | 0.13M | 2.16M | - | - |
| Inventory | 0.00M | 2.93M | 1.22M | 0.32M | 1.42M |
| Accounts payable | 1.01M | 2.23M | 0.59M | 0.16M | 2.23M |
| Accumulated other comprehensive income | -0.10M | - | - | - | - |
| Non currrent assets other | 0.13M | 0.02M | 0.08M | - | - |
| Non current assets total | 0.35M | 0.41M | 0.56M | 4.45M | 5.46M |
| Capital lease obligations | - | - | - | - | 0.52M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Net borrowings | - | - | 2.19M | - | - |
| Total cash from financing activities | 2.58M | 3.93M | 3.58M | 2.00M | 4.72M |
| Net income | -5.18M | -3.48M | -6.28M | -3.03M | -6.18M |
| Change in cash | 1.48M | -0.36M | 0.61M | -1.65M | -0.98M |
| Begin period cash flow | 1.68M | 1.99M | 1.39M | 3.04M | 4.26M |
| End period cash flow | 3.16M | 1.68M | 1.99M | 1.39M | 3.04M |
| Total cash from operating activities | -1.13M | - | - | - | - |
| Issuance of capital stock | - | 4.08M | 1.49M | 2.13M | 4.85M |
| Depreciation | 0.07M | - | - | - | - |
| Change to inventory | 2.92M | - | - | - | - |
| Change to account receivables | 2.76M | - | - | - | - |
| Sale purchase of stock | - | -0.12M | -0.09M | -0.02M | -0.13M |
| Capital expenditures | 0.01M | 0.01M | 0.19M | 0.00M | 0.71M |
| Change in working capital | 3.91M | - | - | - | - |
| Other non cash items | 0.07M | - | - | - | - |
| Free cash flow | -1.14M | -4.26M | -2.84M | -3.46M | -6.26M |
Sector: Consumer Cyclical Industry: Department Stores
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| XEN Xenitra Limited |
- -% |
0.00 | - | 1.19 | 0.46 | 37.26 | 0.37 | -0.77 |
| BGP Briscoe Group Australasia Ltd |
- -% |
3.00 | 13.64 | 11.89 | 0.83 | 2.76 | 1.42 | 8.51 |
| MYR Myer Holdings Ltd |
-0.01 3.85% |
0.25 | - | 5.56 | 0.11 | 0.63 | 0.52 | 44.15 |
Xenitra Limited operates as a brand acceleration, market-access, and distribution company in Australia, Hong Kong, and Mainland China. It offers functional and medical food, such as infant formula, and vitamin mineral and supplement category products; over the counter products, such as non-prescription small molecule medicines and structure function benefit complementary medicines; fast-moving consumer goods (FMCG); nutraceuticals; health and wellness; and personal care products, as well as involved in real world asset tokenisation and nutritional product trading. It sells its products through a network of B2B wholesale, retail distribution, and e-commerce platforms. The company was formerly known as AuMake Limited and changed its name to Xenitra Limited in March 2026. Xenitra Limited was incorporated in 2011 and is based in Brisbane, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Anthony Guarna | Chief Financial Officer | NA |
| Mr. Zhiguo Zhang | Group Chief Operating Officer | NA |
| Mr. Sebastian Andre | Company Secretary | NA |
| Mr. Chen Zhenghai | Group General Manager | NA |
| Ms. Zhao Zhang | Head of China | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.